Palisade Bio (PALI) Net Income towards Common Stockholders (2010 - 2026)
Palisade Bio (PALI) posted quarterly Net Income towards Common Stockholders of -$10.7 million for Q1 2026, down 382.02% year-over-year from $3.8 million in Q1 2025, and down 7.64% quarter-over-quarter from -$10.0 million in Q4 2025.
Powered by 
Analysis
Palisade Bio (PALI) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$10.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 382.02% year-over-year to -$10.7 million; the TTM figure through Mar 2026 stood at -$26.4 million (down 100.13% YoY), while the FY2025 annual figure was -$45.3 million, up 4.19% from the prior year.
- Net Income towards Common Stockholders retreated to -$10.7 million in Q1 2026 per PALI's latest filing, from -$10.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2.2 million in Q1 2025 and bottomed at -$10.7 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$4.1 million across 5 years, with a median of -$3.5 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 92.62% — and 2026, when it sank 382.02%.
- Palisade Bio's Net Income towards Common Stockholders stood at -$3.8 million in 2022, then increased by 17.97% to -$3.2 million in 2023, then slipped by 7.28% to -$3.4 million in 2024, then slumped by 194.75% to -$10.0 million in 2025, then decreased by 7.64% to -$10.7 million in 2026.
- Business Quant data shows PALI's Net Income towards Common Stockholders at -$10.7 million in Q1 2026, -$10.0 million in Q4 2025, and -$2.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | -11.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.70 Mn |
| Mar 31, 2026 | -10.75 Mn |
| Dec 31, 2025 | -9.98 Mn |
| Sep 30, 2025 | -2.87 Mn |
| Jun 30, 2025 | -2.78 Mn |
| Mar 31, 2025 | -2.23 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | -3.49 Mn |
| Jun 30, 2024 | -4.08 Mn |
| Mar 31, 2024 | -3.53 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Jun 30, 2023 | -3.39 Mn |
| Mar 31, 2023 | -2.34 Mn |
| Dec 31, 2022 | -3.85 Mn |
| Sep 30, 2022 | -4.42 Mn |
| Jun 30, 2022 | -2.34 Mn |
| Mar 31, 2022 | -3.89 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -3.04 Mn |